ELIOS研究:EGFR突变晚期NSCLC一线奥希替尼获得性耐药分子谱分析
ELIOS是一项前瞻性多中心分子谱分析研究,纳入154例EGFR突变晚期NSCLC患者,比较一线奥希替尼治疗前与进展后的肿瘤活检。52例配对组织NGS显示最常见获得性改变为MET扩增(17%)、CDKN2A/CDKN2B缺失(15%)、MTAP缺失(13%)和EGFR C797S(13%)。蛋白基因组分析显示TROP2在基线和进展后均高表达;组织与血浆NGS互补,82%进展后配对样本可检出潜在耐药改变。
要点
- 一线奥希替尼进展后耐药机制异质,MET扩增和EGFR C797S常见。
- TROP2在基线和进展后均高表达,不受基因改变影响。
- 组织与血浆NGS互补,82%进展后样本可检出耐药改变。
核心结论
- ELIOS证实一线奥希替尼获得性耐药机制异质,需广谱或多通路治疗策略。
研究设计与样本
- 前瞻性多中心分子谱分析研究(NCT03239340),纳入154例EGFR突变晚期NSCLC患者。
- 52例有配对治疗前和进展后组织活检NGS结果。
- 蛋白基因组分析基线和进展后样本分别为32例和18例。
- 进展后配对组织和血浆样本NGS分析纳入51例。
主要发现
- 进展后最常见获得性改变为MET扩增(17%)、CDKN2A/CDKN2B缺失(15%)、MTAP缺失(13%)和EGFR C797S(13%)。
- TROP2在基线和进展后均高表达,与观察到的基因改变无关。
- 进展后配对组织和血浆样本中,82%通过NGS检出潜在耐药改变。
临床怎么用
- 一线奥希替尼进展后应综合考虑组织与血浆NGS以全面评估耐药机制。
- 耐药机制异质性提示可能需要针对多通路的联合治疗策略。
- TROP2高表达为潜在治疗靶点,但需进一步临床验证。
局限性
- 仅52例患者有配对组织活检NGS结果,样本量有限。
- 蛋白基因组分析样本量较小(基线32例,进展后18例)。
- 获取进展后组织活检存在挑战,可能影响耐药谱全面性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: ELIOS (NCT03239340) prospectively compared tumor biopsies obtained pre-treatment and post-progression to characterize acquired resistance mechanisms to first-line osimertinib in epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC). Of 154 patients enrolled, 52 patients had next-generation sequencing (NGS) results from paired tissue biopsies. The most common acquired alterations at progression were MET amplification (17%), deletion of CDKN2A/CDKN2B (15%) and MTAP (13%), and EGFR C797S (13%). Proteogenomic analysis (n = 32 at baseline and n = 18 post-progression) showed TROP2 was highly expressed at baseline and post-progression, irrespective of genetic alterations observed. In a separate analysis of patients with matched tissue and plasma samples post-progression (n = 51), 82% had potential resistance alterations by NGS, demonstrating the complementary roles of tissue and plasma NGS. These results highlight the challenges of obtaining tissue biopsies in patients with NSCLC progressing on targeted therapy, the potential for heterogeneous resistance, and the need for broad-acting treatment strategies. SIGNIFICANCE: ELIOS confirmed acquired resistance mechanisms to first-line osimertinib in a prospective, molecular profiling study of paired pre- and post-treatment tissue samples and provided the first proteogenomic characterization before/after osimertinib, identifying novel proteomic markers. ELIOS showed the potential for heterogeneous resistance, highlighting that strategies targeting multiple resistance pathways may be required.
引用
- Piotrowska Z, Ahn MJ, Voon PJ, et al. ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib. Cancer Discov. 2026. PMID: 41790042. doi:10.1158/2159-8290.CD-25-0960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。